NCBIO members had a full program of activities at the Annual Meeting. Leadership and Transitions was the topic of the opening presentation by Jeff George, formerly with the Novartis Group. David Hollinrake of Syngenta Seeds talked about the new era of innovation in agriculture, and Morten Nielsen discussed Novo Nordisk's decision to invest $2B in a new production facility in North Carolina.
JC Scott, AdvaMed; Allison Giles, Cook Medical Group; and Gavin Lindberg, Grifols talked with members about federal actions on health care, tax reform, repeal of medical device tax and other issues. Spotlight on Markets was the topic of a panel with Christy Shaffer (Moderator), Hatteras Ventures; Jim Douglas and Neil Riley, Piper Jaffray; and Todd Schwarzinger, Silicon Valley Bank.
Thanks to our sponsors for the Annual Meeting: Platinum: Bioventus, Cook Medical, Novo Nordisk and VWR; Gold: Bayer, BioNetwork, Fujifilm Diosynth, Grifols, Merz and The Conafay Group; Silver: AdvaMed, ALT, BIO, Kymanox, Office Depot, Patheon, UCB Biosciences, UniFirst/UniClean and UPS; and Bronze: BD, Business Wire, EY, G1 Therapeutics, Nikon, Novartis, Novozymes, PhRMA, PPD, and Royal Hill Consulting
"Company Development: Managing Risk and Brand" was the topic of discussion at the NCBIO Annual Meeting Dinner. NCBIO President Sam Taylor moderated a panel with Kristen Kraeger and Jim Walters of Aon Risk Solutions; Ford Worthy, Pappas Ventures; Michelle Douglas, Ketchum; and Steve Peterson, Trans Discovery.
Members of the Legislative Life Science Caucus Members got a look at the NCBioImpact education programs September 22. Staring at the BTEC building at NC State University, lawmakers toured the BTEC labs and the NC Community College BioNetwork aseptic suite, which is being updated. They also visited the BRITE program at North Carolina Central University. “The institutions did a great job of educating lawmakers about the needs and also outlined the success of the programs in providing graduates and training for incumbent workers,” stated NCBIO President Sam Taylor. “We will be providing tours in other parts of the State so lawmakers can see the diversity of the industry in North Carolina.”
“Business Transformation: Approaches + Lessons Learned,” was the topic at the September NCBIO Biotech Manufacturers Forum (BMF) meeting. John Cassimatis of TayganPoint Consulting Group told participants that the drivers for business transformation are leadership changes, mergers and acquisitions, new regulation and compliance changes, health of pipeline and lifecycles, and technology.
House Senior Appropriations Chairman, Rep. Nelson Dollar (R-Wake), and Life Science Co-Chairs, Rep. Susan Martin (R-Pitt, Wilson), Rep. Ed Hanes (D-Forsyth) and Sen. Angela Bryant (D-Halifax, Nash, Vance, Warren and Wilson) talked with NCBIO Members during the annual Legislative Forum.
Rep. Dollar encouraged members to become advocates for SBIR matching grant funds, which were not included in the 2017-18 budget. He encouraged them to tell success stories about companies that had benefited from the funds. Rep. Martin talked about the importance of collaboration between industry and legislators. Rep. Hanes discussed the importance of working with researchers at the various universities in the state to drive innovation. Sen. Bryant asked members to develop graphics and information demonstrating the range of life science companies and the locations across North Carolina.
North Carolina has a long commitment to growing our state’s life science industry and that is indicated in reports by PhRMA highlighting North Carolina as a leader in "in Biotechnology Innovation and Education Amid Growing Global Competition."
Life Science programs received support from the North Carolina General Assembly. Click here for more information.
Panelists had a lot of advice for NCBIO members seeking approval from the FDA. The session was led by Daniel Schultz, M.D., F.A.C.S., Principal, Medical Devices & Combination Products, Greenleaf Health and former Director of the Center for Devices and Radiological Health, Food and Drug Administration. Speakers joining the discussion included: Patrick Daly, President and Chief Executive Officer, Cohera Medical; Tammy Carrea, Vice President of Quality & Regulatory for Baebies; and Tim Willis, Chief Executive Officer and Founder, MED1 Ventures. Thanks to former NCBIO Board Chairman Peyton Anderson, CEO of Affinergy, for providing opening and closing comments and to PwC, Technosoft Innovations, and Wyrick Robbins for sponsoring the Forum.
The new Legislative Joint Life Science Caucus is quickly learning about the industry in North Carolina. At a meeting May 3rd, Kristen Parde of PhRMA discussed how medicines benefit patients, the health care system and the economy. On May 17th, the Caucus received a briefing on the impact of clinical research organizations (CROS) in North Carolina. Rachael Fones and Patrick Jordan of QuintilesIMS discussed the clinical trial process for new drugs and the economic impact of the industry in the State. At the May 31st meeting, the Caucus heard about university collaborations from Dr. James Ryan, Dean of the Joint School of Nanoscience and Nanoengineering School at NC A&T University and UNC-Greensboro, and Dr. Faye Calhoun and Dr. Jonanthan Sexton from BRITE at NC Central University.
Legislators and NCBIO members talked about the future of the life science industry in North Carolina at the 2017 Annual Legislative Reception on April 5th. Thanks to AbbVie, Amgen, Astellas, Bayer, Biogen, Johnson & Johnson, Lilly, Novozymes, PhRMA, and Syngenta for helping make this event possible.
NCBIO was a co-sponsor with the UNC School of Pharmacy and NCCU BRITE for a luncheon hosting former FDA Commissioner Robert Califf. NCBIO Biotech Manufacturers Forum Manager John Wagner and Dr. Califf talk prior to the luncheon.
Companies can use a variety of funding options for early seed and start-up stages according to panelists at the NCBIO Luncheon and Forum, February 7th. NCBIO members heard different perspectives from representatives who discussed venture funding, grant and loan programs, non-dilutive funding, pharmaceutical partnering and more.